ACESO currently uses a combination of unbiased and targeted laboratory testing ‘multi-omic’ platforms (transcriptomic, proteomic, metabolomic etc.) to perform a comprehensive characterization of the temporal dynamics of the host response to infection. Our vision is to translate this systems biology approach to develop and deploy rapid point-of-care diagnostics/prognostics in resource-limited settings across the globe. We envision a time where host-immune biomarker-driven sepsis endotypes leading to evidence-based clinical management will become standard of care in sepsis/severe infections.

To that end, ACESO is engaged in observational studies of sepsis in Cambodia, Ghana, Liberia, Uganda, Madagascar, Peru and the United States. Patients presenting to participating hospitals with severe illness and a suspected infection are enrolled in an observational study of sepsis. A variety of biological samples are collected to examine the molecular characteristics of each patient’s host response to infection.